CalciMedica to Participate in the Jones Healthcare and Technology Innovation Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies for inflammatory and immunologic conditions, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference.
The company's CEO, Rachel Leheny, Ph.D., will deliver a presentation on Wednesday, April 9, 2025, at 11:00 a.m. PT. Interested parties can access the live webcast through CalciMedica's IR website in the 'Upcoming Events' section. The presentation recording will remain available on the company's website for a 90-day period.
Details
News Market Reaction – CALC
The recorded move for CALC in the trading session of this news was +2.09%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
A live webcast of the presentation can be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/. A replay of the webcast will be archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected around the end of 2025 and continuing to support the ongoing investigator-initiated Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with an update expected in the second half of 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in
Contact Information
Argot Partners
Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-participate-in-the-jones-healthcare-and-technology-innovation-conference-302416105.html
SOURCE CalciMedica, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.